BioNTech explains that mRNA vaccines allow for a standardised production pipeline that is able to produce an experimental batch within the first week.
The active component of the vaccine, the mRNA, can be substituted with the mRNA sequence for the altered virus allowing for an updated vaccine.
The new vaccine will still need to be tested, followed by production and distribution of the updated vaccine.
The mRNA vaccine production process greatly reduces the timescale of the overall process of vaccine rollout.
Source: | This article first appeared on Express.co.uk
Original Article
